Immatics N.V., a German biotech, focuses on training T-cells to target cancer ... that is intended to engage a more potent antitumor immune response. At the SITC meeting in November, this second ...
Most clinically relevant T-cell receptor (TCR)-engineered T cells are typically tested in immunocompromised mice, allowing human T-cell engraftment but failing to replicate the complex interactions of ...
In addition to using gemcitabine and the natural killer cells that are TGF-β imprinted, we also are combining an anti-GD2 antibody called naxitamab that's provided by Y-mAbs. Naxitamab, as I said, is ...